The global antiplatelet drugs market was estimated to be US$ 2,154.54 Million in 2022 and is expected to reach US$ 4,470.33 Million by 2032 at a CAGR of 7.6%.
Antiplatelet drugs are medications that inhibit the ability of platelets to clump together and form blood clots. Platelets play a crucial role in the blood clotting process, which is essential for preventing excessive bleeding following an injury. However, when platelets aggregate within the blood vessels, they form clots that can impede blood flow to vital organs, leading to severe health issues such as stroke and heart attacks.
Antiplatelet drugs function by suppressing platelet activity, thereby reducing their tendency to aggregate and form clots. There are various types of antiplatelet drugs, including ADP receptor inhibitors, aspirin, phosphodiesterase inhibitors, and glycoprotein IIb/IIIa inhibitors.
Aspirin, a nonsteroidal anti-inflammatory drug (NSAID), is commonly used as an antiplatelet agent. It operates by inhibiting the action of the enzyme cyclooxygenase (COX), which is involved in prostaglandin production. Aspirin blocks COX and attenuates the production of thromboxane A2, a platelet activator. On the other hand, ADP receptor inhibitors belong to a class of antiplatelet drugs that work by blocking the P2Y12 receptor found on the platelet surface.
Phosphodiesterase inhibitors constitute another class of antiplatelet drugs, which function by elevating the concentration of cyclic adenosine monophosphate (cAMP) within platelets.
The growth of the antiplatelet drugs market is being driven by the increasing chronicity of cardiovascular diseases worldwide. The rising prevalence of cardiovascular diseases, such as strokes and heart attacks, is a significant factor driving the demand for antiplatelet drugs. Cardiovascular diseases are a leading cause of death globally, and factors such as the rise in the geriatric population, smoking and drinking habits, and unhealthy lifestyles contribute to the increased occurrence of these diseases.
According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of deaths worldwide. It is estimated that approximately 20 million people die from cardiovascular diseases globally each year. Antiplatelet drugs play a vital role in the prevention and treatment of cardiovascular diseases by preventing the formation of blood clots and subsequent occurrences of heart attacks and strokes. Consequently, there is a growing need for antiplatelet drugs to address these healthcare challenges.
Innovation in drug development is also augmenting market statistics. Key pharmaceutical manufacturers are involved in making improvements to existing drugs to increase their safety, efficiency, and patient outcomes. Targeted and efficient drug delivery systems can help ensure that the drug reaches the intended site of action, reducing the chances of side effects and increasing its efficiency. For instance, drug-eluting stents, which slowly release an antiplatelet drug to prevent blood clotting and restenosis in patients undergoing angioplasty, serve as an example of an innovative drug delivery system for antiplatelet drugs.
The development of new antiplatelet drugs is also creating opportunities for market players. For instance, researchers at the University of Illinois (UIC) have created a medication that prevents blood clots without raising the risk of bleeding.
Based on drug type, the market is segmented into irreversible cyclooxygenase (COX) inhibitors, adenosine diphosphate (ADP) receptor inhibitors, glycoprotein IIb/IIIa inhibitors, adenosine reuptake inhibitors, thromboxane inhibitors, and phosphodiesterase inhibitors. Irreversible cyclooxygenase inhibitors dominate the market and are expected to continue in the forecasted period.
Irreversible COX inhibitors, also called aspirin drugs, irreversibly inhibit both COX-1 and COX-2 enzymes by acetylating a serine residue in the active site of the enzyme. This irreversible binding results in permanent inhibition of enzyme activity. Aspirin is one of the most well-known irreversible COX inhibitors and is commonly used as an anti-inflammatory and pain reliever. Other irreversible COX inhibitors include diclofenac, ibuprofen, and indomethacin. An increase in the adoption of COX inhibitors is projected to fuel the market in the coming years.
In terms of indication, the antiplatelet drugs market is segmented into myocardial infarction, arterial thrombosis, angioplasty, and percutaneous coronary intervention. Myocardial infarction (MI), also known as a heart attack, occurs when the blood supply to the heart muscle is blocked by a blood clot, leading to damage to the heart tissue and even causing death.
Percutaneous coronary intervention (PCI) is a procedure used to treat a narrowed or blocked coronary artery to restore the flow of blood to the heart muscle. PCI is commonly performed on patients suffering from acute myocardial infarction (AMI) because it can swiftly restore the flow of blood to the affected portion of the heart and prevent further damage to it. The antiplatelet technique is found effective in patients undergoing percutaneous coronary intervention or myocardial infarction.
Based on administration, the antiplatelet drugs market is divided into two categories: oral and injectable. The oral route of administration is the most common route, as it is easier to administer, convenient, and provides predictable absorption of antiplatelet drugs.
In terms of distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies accounted for a major share in 2022 and are likely to dominate the global antiplatelet drugs market in the forecasted period. The rise in the availability of oral drugs in hospital pharmacies is a major factor propelling the growth of this segment. This is likely to boost the growth of the antiplatelet market in the years to come.
Geographically, the global antiplatelet drugs market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America.
Following are some of the major trends in these regions –
North America: North America dominates the global antiplatelet drugs market due to the increased adoption of newer technologies and the growing demand for disease-specific treatments. Additionally, the increased expenditure on the healthcare sector and the presence of key players in the region are propelling the growth of antiplatelet drugs.
Europe: Europe is another prominent market where the growing number of myocardial infarction cases and the increase in government spending are boosting growth.
Asia-Pacific: The Asia-Pacific region represents a rapidly expanding market for global antiplatelet drugs. The rising healthcare expenditure and growing emphasis on personalized medicine have fueled the demand for antiplatelet drugs. Countries like China, Japan, India, and South Korea are witnessing significant growth in the antiplatelet drugs market due to factors such as improving healthcare infrastructure and increasing disposable income.
Middle East and Africa: The Middle East and Africa region are witnessing gradual but steady growth in the global antiplatelet drugs market. Factors such as increasing healthcare investments and the adoption of advanced healthcare technologies have contributed to market expansion. Countries like the United Arab Emirates, Saudi Arabia, and South Africa are leading the market in the region. However, the market is still relatively nascent compared to other regions.
South America: South America has also witnessed notable growth in the global antiplatelet drugs market. Factors such as the rising burden of cardiovascular diseases, increasing awareness about personalized medicine, and advancements in healthcare infrastructure have contributed to market expansion in the region. Brazil, Argentina, and Colombia are the key markets in South America, driven by the presence of well-established healthcare facilities and a growing focus on precision medicine.
In January 2022, Sanofi Aventis and Bristol Myers Squibb, pharmaceutical companies, announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental new drug application (sNDA) for their antiplatelet agent. This drug aims to reduce death rates from any cause and the combined endpoint of rein fraction, stroke, or death in patients with acute ST-segment elevation myocardial infarction (STEMI).
STEMI is a severe heart attack characterized by the blockage of the coronary artery. These blockages can lead to the formation of blood clots in the arteries, posing a life-threatening condition that can result in death.
Sanofi Aventis and Bristol Myers Squibb's collaboration and successful FDA approval of the antiplatelet agent highlight their strategy to enhance their product portfolio and address the critical need for effective treatments in patients with acute STEMI.
By gaining regulatory approval, the companies can position themselves as key players in the market and capture a significant share in the treatment of this condition. This growth strategy allows them to expand their market presence and increase their competitive advantage by offering innovative and life-saving solutions for patients suffering from acute STEMI.
According to the global antiplatelet drugs market trends, the global industry is fragmented with the presence of a large number of global and international markets.
The leading players in this segment include Alta Laboratories, AstraZeneca, Bayer Pharmaceuticals, Mylan Pharmaceuticals, Bristol-Myers Squibb Company, Pharma science, Portola Pharmaceuticals, Sanis Health, Syntex, and others.
Based on Drug Type
Based on Indication
Based on Administration:
Based on Distribution Channel
Based on Region
The antiplatelet drugs market is expected to reach US$ 4,470.33 Million by 2032.
The antiplatelet drugs market is expected grow at a CAGR of 7.6% between 2023 to 2032.
The antiplatelet drugs market was estimated to be US$ 2,154.54 Million in 2022.
The rising prevalence of cardiovascular diseases, such as strokes and heart attacks, is a significant factor driving the demand for antiplatelet drugs.
North America dominates the global antiplatelet drugs market due to the increased adoption of newer technologies and the growing demand for disease-specific treatments.
Alta Laboratories, AstraZeneca, Bayer Pharmaceuticals, Mylan Pharmaceuticals, Bristol-Myers Squibb Company, Pharma science, Portola Pharmaceuticals, Sanis Health, Syntex among others, are the major players in the antiplatelet drugs market.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved